Continuous vs. Batch Processing for Biopharma Manufacturing
What are the differences between batch and continuous processing? This week we unpack the pros and cons of both models, as well as the hybrid processing approach.
What is Batch Processing
Batch processing is the traditional and dominant method in biopharma manufacturing. This approach involves producing a specifically defined quantity of a product through a series of discrete, sequential steps. Each stage of the process, from cell culture to final formulation, must be completed for the entire batch before moving on to the next.
An easy way to understand batch processing is that baked goods are created and baked in batches, with multiple identical products being produced at once. However, you cannot bake the items until the batter is complete.
The primary reason for its long-standing preference in the industry is the control and quality assurance it provides. By segmenting the process into distinct batches, manufacturers can conduct rigorous quality checks at each stage.
If a batch fails a quality test, it can be quarantined or discarded, preventing a flawed product from progressing further and minimizing risk. This level of oversight is crucial for meeting the stringent regulatory requirements of the biopharma industry, where product safety and efficacy are paramount.
Benefits
As mentioned above, one of the primary benefits of batch processing, both in biopharma and other industries, is the ability to perform various quality tests during different steps of the process. Since each item is completed during a multi-step process, quality checks allow you to catch inconsistencies or issues early on, when you can either correct the batch there, or stop production of a non-viable batch early to save time.
Batch processing is also widely known to be better for products that require more customization. In downtime between batches, you are able to adjust the parameters in a certain step to the requirements unique to that batch.
Batch processing also provides a clear advantage in maintaining sterility and cleanliness. The defined pauses between each production run allow for a complete and thorough cleaning and sterilization of equipment. This is a critical factor in biopharma, where even the smallest contamination can render an entire batch unusable.
The downtime also accommodates the use of single-use technologies like disposable bioreactors, which can be swapped out between batches to eliminate the risk of cross-contamination and the need for complex cleaning validation.
Concerns & Pitfalls
Batch processing, while well-established and trusted, presents several concerns and pitfalls in biopharma manufacturing. One of the most significant issues is its inherent inefficiency. The process is characterized by a series of steps, each requiring a separate setup, operation, and teardown. This leads to longer production cycles, increased downtime between batches, and a large facility footprint to accommodate all the equipment.
Additionally, while quality control is often seen as a pro for batch processing, the nature of batch processing can also introduce inconsistencies between batches, even when using the same raw materials and procedures.
These variations can arise from small differences in processing times, temperatures, or human handling. Furthermore, quality checks are typically performed after each step is completed. If a problem is discovered late in the process, the entire batch may need to be discarded, resulting in significant financial losses and delays.
What is Continuous Processing?
Defined simply, continuous processing is when a single component or product is manufactured non-stop, meaning there is no pause from start to completion. Commonly, you will see continuous processing in the manufacturing of products that require very little customization, or need to be produced in high volumes. Some classic examples of continuous processing include paper manufacturing and manufacturing chemicals in a refinery.
In the biopharma industry, continuous processing is increasingly being adopted for similar reasons. It's particularly well-suited for high-volume biopharmaceuticals like certain monoclonal antibodies (mAbs) that have high market demand and do not require significant customization. The constant flow allows for consistent production and can significantly reduce the manufacturing footprint and associated costs.
Benefits
When discussing continuous processing, one of the main advantages discussed is the ability to produce much higher volumes of product. For example, one of the main models we think of in modern bulk manufacturing is a production line, which is continuous manufacturing. As discussed above, this continuous production of high volumes can often be cost and time saving.
Additionally, continuous processing boasts real-time control and improved product quality. Unlike batch processing, where quality checks are performed after each step, continuous systems integrate Process Analytical Technology (PAT). This allows for constant, in-line monitoring of critical quality attributes, enabling immediate adjustments to be made to the process.
Beyond just efficiency, continuous processing offers a crucial advantage when dealing with fragile or unstable biological materials. Many biopharmaceuticals are sensitive to environmental conditions and can degrade over time.
In a continuous system, the product is removed from the bioreactor as soon as it's produced, minimizing its exposure to conditions that could harm its quality and efficacy. This harvesting method protects the product and helps maximize the overall yield, a critical factor for expensive and complex therapies.
Concerns & Pitfalls
Despite its numerous advantages, continuous manufacturing is not without its challenges. One of the most significant barriers to its adoption is the high initial investment required. The specialized equipment and complex automation systems needed for a continuous setup are costly to purchase and install.
Additionally, the regulatory landscape, which has been built around batch processing for decades, presents a formidable hurdle. Gaining regulatory approval for a continuous process can be a lengthy and resource-intensive effort, as manufacturers must prove the process's safety, efficacy, and consistency to a well-established set of guidelines for batch production.
These integrated systems are highly complex and require a specialized, skilled workforce to operate, maintain, and troubleshoot. A failure in one part of the continuous production train can halt the entire process, unlike in a batch system where a single failed step might only impact a specific part of the process.
Finally, while continuous is excellent for producing large volumes of a single product, it is inherently less flexible for creating customized therapies or a diverse portfolio of products. Retooling a continuous line for a different product can be far more challenging and time-consuming than adjusting a batch-based process.
Can You Have a Successful Hybrid Model?
Recognizing the distinct benefits and limitations of both batch and continuous processing, the biopharma industry is increasingly embracing a hybrid manufacturing model. This approach combines elements of both systems to create a more flexible and efficient production train that is tailored to a specific product or stage of development. The goal is not to force a single model onto every step, but to strategically use each method where it provides the most value.
A common hybrid setup involves running the upstream process, such as cell culture, in a continuous or semi-continuous mode to maximize cell density and productivity. The product is then continuously harvested and fed into a batch downstream process for purification and quality testing.
This configuration leverages the high efficiency of continuous upstream production while retaining the established, high-level quality control and flexibility of batch-based purification. A set-up like this is especially useful for early-stage clinical manufacturing, where the priority is to quickly generate material for trials while maintaining strict quality standards that are well-understood by regulatory bodies.
Incorporate Scalability & Flexibility into Any Process
Regardless of your manufacturing approach, whether it be continuous, batch, or a hybrid, at HPNE, a Getinge Company, we have optimized our product portfolio to be equipped to handle all of your bioprocess challenges.
Our HPConnexx™ Single-Use Assemblies have consistently demonstrated their ability to scale-up with our customers as their processes grow. With years of experience, our expert team can design an assembly specific to your unique process. Additionally, our brand agnostic designs mean we are never limited in our assembly capabilities due to the company or brand of a part.
We would love to start a conversation about your manufacturing approach, and see how our innovative bioprocess solutions like Quaternary Diaphragm Pumps, Single-Use Bioreactors, and Stainless Steel Harvest Cart can help operations at your facility become more efficient. Reach out to our team at info@hp-ne.com, or visit or contact us page. A member of the team will be happy to get back to you shortly!
Share article
About HPNE
As the industry needs grow, High Purity New England, Inc. continues to supply the biopharmaceutical industry with a range of innovative products, from drug discovery and development to fill-finish, including their flagship product, custom single-use assemblies, as well as pumps, sensors, bioreactor systems, storage and handling solutions and other single-use solutions. Along with their own manufactured products for the global market, they are also a distributor for more than 18 brands in North America.
